Status:
ACTIVE_NOT_RECRUITING
Radiofrequency-responsive Layered Double Hydroxides for Enhanced Arterial Embolization and Thermal Immunotherapy in Hepatocellular Carcinoma
Lead Sponsor:
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Conditions:
Liver Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
Liver cancer is one of the most common malignant tumors and the third leading cause of cancer-related deaths globally. Recent epidemiological studies show that in China, liver cancer ranks fourth in i...
Eligibility Criteria
Inclusion
- individual tumors were less than 5 cm in diameter. The number of multiple tumors was not more than 3, and the diameter of each tumor was not more than 3 cm, and there was no extrahepatic metastasis. Child-Pugh A or B; There is no refractory ascites or irremediable coagulation dysfunction; Prothrombin activity higher than 40%, platelet count more than 500,000/L; RFA with healing purpose.
Exclusion
- presence of vascular infiltration and extrahepatic metastasis; Severe clotting disorders; Severe cardiopulmonary insufficiency or uncontrolled liver decompensation.
Key Trial Info
Start Date :
September 11 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2026
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT06966986
Start Date
September 11 2024
End Date
October 1 2026
Last Update
May 13 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Fourth Affiliated Hospital Zhejiang University School of Medicine
Yiwu, Zhejiang, China, 322000